Olmesartan
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Olmesartan
- Molecular weight
- 446.51
- Structure (SMILES)
- CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
- 1h imidazole 5 carboxylic acid 4 1 hydroxy 1 methylethyl 2 propyl 1 2 1h tetrazol 5 yl 1 1 biphenyl 4 yl methyl
- 1H-IMIDAZOLE-5-CARBOXYLIC ACID, 4-(1-HYDROXY-1-METHYLETHYL)-2-PROPYL-1-((2'-(1H-TETRAZOL-5-YL) (1,1'-BIPHENYL)-4-YL)METHYL)-
- azelnidipine 8 mg and olmesartan 20 mg
- nsc 759810
- NSC-759810
- olmesartan
- Olmesartan
- olmesartan [INN]
- OLMESARTAN [MI]
- OLMESARTAN [USAN]
- OLMESARTAN [VANDF]
- Olmesartan [WHO-DD]
- olmesartan inn
- OLMESARTAN MEDOXOMIL IMPURITY A [EP IMPURITY]
- olmesartan medoxomil impurity a ep impurity
- olmesartan medoxomil impurity olmesartan
- olmesartan medoxomil impurity olmesartan usp impurity
- Olmesartan medoxomil impurity, olmesartan-
- OLMESARTAN MEDOXOMIL IMPURITY, OLMESARTAN- [USP IMPURITY]
- olmesartan mi
- olmesartan usan
- olmesartan vandf
- olmesartan who dd
- rnh 6270
- RNH-6270
- CAS registry numbers
- 144689-24-7
- ChEMBL ID
- CHEMBL1516
- InChIKey
- VTRAEEWXHOVJFV-UHFFFAOYSA-N
- PubChem compound IDs
- 158781
- RxNorm IDs (RxCUI)
- 321064
- FDA ingredient codes (UNII)
- 8W1IQP3U10
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- olmesartan
- Type
- Synthetic organic
- Drug name stem
- -sartan
- Approval recorded by Guide to Pharmacology
- Yes
- Action
- Antagonist
- Action type
- Antagonist
- Target
- AT1 receptor
- Gene symbol
- AGTR1
- Protein identifier
- P30556
- Median affinity
- 8.1
- Affinity units
- pIC50
- Primary target
- Yes
- Mechanism
- Type-1 angiotensin II receptor antagonist
- Action type
- Antagonist
- Target
- Type-1 angiotensin II receptor
- Protein identifier
- P30556
Open Targets mechanisms
- Mechanism
- Type-1 angiotensin II receptor antagonist
- Action type
- Antagonist
- Target
- Type-1 angiotensin II receptor
- Condition
- Atrial Fibrillation
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000275
- Subject identifier
- D001281
- Condition
- Hypertension
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000537
- Subject identifier
- D006973
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000694
- Subject identifier
- D045169
- Condition
- Stroke
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000712
- Subject identifier
- D020521
- Condition
- Arrhythmias, Cardiac
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004269
- Subject identifier
- D001145
- Condition
- Essential Hypertension
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0001134
- Subject identifier
- D000075222
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000537
- Condition identifier
- EFO_0000712
- Highest recorded phase
- 2
- Condition identifier
- HP_0000822
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0001134
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0001422
- Condition identifier
- MONDO_0002525
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005044
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005148
- Condition identifier
- MONDO_0021187
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 3
- Condition identifier
- MONDO_1060198
- Highest recorded phase
- 2
- Condition identifier
- Orphanet_309005
- Highest recorded phase
- 3
- Event
- abdominal hernia
- Reports
- 67
- Reporting signal score
- 177.654
- Event
- acquired oesophageal web
- Reports
- 29
- Reporting signal score
- 112.812
- Event
- acute kidney injury
- Reports
- 1,098
- Reporting signal score
- 1,936.97
- Event
- aortic valve stenosis
- Reports
- 12
- Reporting signal score
- 46.5893
- Event
- barrett's oesophagus
- Reports
- 75
- Reporting signal score
- 239.577
- Event
- blood pressure increased
- Reports
- 186
- Reporting signal score
- 106.864
- Event
- bronchial secretion retention
- Reports
- 12
- Reporting signal score
- 54.7947
- Event
- bronchial wall thickening
- Reports
- 12
- Reporting signal score
- 57.3636
- Event
- chest x-ray abnormal
- Reports
- 12
- Reporting signal score
- 37.6867
- Event
- cholecystitis
- Reports
- 101
- Reporting signal score
- 193.669
- Event
- cholecystitis chronic
- Reports
- 97
- Reporting signal score
- 371.799
- Event
- cholelithiasis
- Reports
- 193
- Reporting signal score
- 336.088
- Event
- chronic kidney disease
- Reports
- 289
- Reporting signal score
- 654.08
- Event
- clostridium difficile colitis
- Reports
- 74
- Reporting signal score
- 115.936
- Event
- coeliac disease
- Reports
- 275
- Reporting signal score
- 1,002.69
- Event
- colitis microscopic
- Reports
- 83
- Reporting signal score
- 208.913
- Event
- colitis ulcerative
- Reports
- 108
- Reporting signal score
- 134.383
- Event
- colon adenoma
- Reports
- 42
- Reporting signal score
- 121.952
- Event
- constipation
- Reports
- 622
- Reporting signal score
- 746.102
- Event
- dehydration
- Reports
- 267
- Reporting signal score
- 178.326
- Event
- diarrhoea
- Reports
- 802
- Reporting signal score
- 364.793
- Event
- diverticulitis
- Reports
- 592
- Reporting signal score
- 1,678.81
- Event
- diverticulum
- Reports
- 580
- Reporting signal score
- 2,219.68
- Event
- diverticulum intestinal
- Reports
- 484
- Reporting signal score
- 2,075.11
- Event
- dizziness
- Reports
- 625
- Reporting signal score
- 301.511
And 48 more, listed on the interactive page.
- NCT00098137
- NCT00139698
- NCT00902538
- NCT01599104
- NCT01615198
- NCT01785472
- NCT00362115
- NCT00696241
- NCT00696436
- NCT00759551
- NCT01613209
- NCT01692301
- NCT01870739
- NCT01876368
- NCT02483936
- NCT02493322
- NCT05103332
- NCT05110898
- NCT03655964
- NCT04606563
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 3
- Polar surface area
- 129.81
- Calculated partition coefficient (ALogP)
- 3.66
- Calculated partition coefficient (XLogP)
- 3.2
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 8
- Heavy atoms
- 33
- Molecular formula
- C24H26N6O3
- Monoisotopic mass
- 446.20663871
- Natural product
- Yes
- Recorded assays
- 760
- Active assays
- 13
- Confirmatory
- Other
- Screening
- Antihypertensive Agents
- Angiotensin II Type 1 Receptor Blockers
Oral bioavailability
- Median
- 26
- Mean
- 26
- Minimum
- 26
- Maximum
- 26
- Unit
- %
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (48)
- A Clinical Trial to Evaluate the Efficacy and Safety of Olmesartan/Amlodipine/Rosuvastatin Combination Treatment in Patients With Concomitant Hypertension and Hyperlipidemia
- A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension
- Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy
- An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.
- Angiotensin Receptor Blocker Combined With Calcium Antagonist Evaluation of Safety and Lowering of Systolic Blood Pressure Study
- Assessment of the Effectiveness of OLMETEC® and OLMETEC PLUS® for Treatment of Hypertension in Stage I and II Patients (Study P05254)(COMPLETED)
- Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance
- Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome
- Clinical Study for Patients With Hypertension Associated With Dyslipidemia
- Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia
- Clinical Trail to Evaluate the Efficacy and Safety of DWJ1451
- Clinical Trial to Evaluate Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult Volunteers
- Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab
- Clinical Trial to Investigate the Efficacy and Safety of DWJ1351
- Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure
- Effect of Olmesartan and Nebivolol on Ambulatory Blood Pressure and Arterial Stiffness in Acute Stage of Ischemic Stroke
- Effect of Olmesartan on Angiotensin(1-7) Levels and Vascular Functions in Diabetes and Hypertension
- Effect of olmesaRtan on Walking distancE and quaLIty of lifE in Peripheral Artery Disease Patients With Hypertension Treated For Intermittent Claudication (RELIEF)
- Effects of Antihypertensive Drugs in Patients With Hypertension and Obstructive Sleep Apnea (OSA)
- Efficacy and Safety of a Therapy Change From Candesartan 32 mg to Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg
In development for (7)
- Atrial fibrillation Phase 3
- Cardiac rhythm disease Phase 3
- COVID-19 Phase 3
- Essential hypertension Phase 3
- Hypertensive disorder Phase 3
- Severe acute respiratory syndrome Phase 3
- Stroke disorder Phase 2
Targets (1)
- AGTR1 Type-1 angiotensin II receptor antagonist